Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Interferon alfa-5 + interferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular, Intravenous, Intralesional
01
Overview
Interferon alfa-5 + interferon alfa-2b is a combination of two type I human recombinant alpha-interferons. Interferons are cytokines with immunomodulatory, antiviral, and antiproliferative properties. Interferon alfa-2b is widely used for the treatment of chronic hepatitis B and C infections, certain cancers (such as hairy cell leukemia, malignant melanoma, follicular lymphoma), AIDS-related Kaposi's sarcoma, and genital warts[1][3][5]. Its mechanism of action involves binding to the interferon alpha/beta receptor complex (IFNAR1/IFNAR2) on cell surfaces to activate the JAK/STAT signaling pathway. This leads to modulation of immune responses and induction of genes that inhibit viral replication and tumor growth[3][6][8]. The specific role or clinical use for combining interferon alfa-5 with interferon alfa-2b is not well established in standard practice; most clinical data pertain to individual subtypes such as alpha 2a or 2b.
- Brand names
- Intron A
- Other names
- interferon-α5 + interferon-α2bIFN-alpha5 + IFN-alpha2bIFN-α5 + IFN-α2b
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on Interferon alfa-5 + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interferon alfa-5 + interferon alfa-2b.